Everyone Is Copying You. Was Protecting Your IP a Waste of Money?

Why Intellectual Property (IP) protection is essential, why infringement can still happen, and what sophisticated innovators should actually do when they cannot afford to sue everyone.

There is a particularly cruel moment in the life of a successful innovator. It usually begins with a phone call.

“We've just seen another competitor doing it.” Another competitor. Another product. Another website. Another development. Another brand. Another business is apparently doing something remarkably similar to the innovation that your client spent years developing. And then comes the inevitable question: “What's the point of protecting our intellectual property if we can't afford to sue everybody who copies us?” It is an excellent question.

But it contains a dangerous misconception. The answer is not that IP protection is unnecessary because enforcement can be expensive. Quite the opposite.

Protecting available intellectual property is a commercial and legal MUST.

It is part of the foundation of an innovative business. But protection is not a force field. It does not automatically stop competitors from infringing. It does not guarantee that competitors will seek legal advice. And it certainly does not guarantee that, after receiving legal advice, they will politely comply with the law. Some competitors will. Some will misunderstand the law. And some will understand it perfectly well and decide:

“We'll take our chances.”.

That is the uncomfortable reality. So the real question is not: “Can we afford to sue everyone?”. The real question is: “How do we build an IP position that protects the business, creates leverage, deters copying, generates commercial opportunities and allows us to enforce selectively—without having to litigate against everybody?” That is a much better question. And it has a very practical answer.

The story of NovaCare

Consider a fictional company. Let's call it NovaCare. NovaCare operated retirement communities. Several years earlier, its founders noticed something that seemed simple once they had seen it. People entering retirement did not necessarily want to make a series of forced moves as they aged.

They wanted a real home. They wanted independence. They wanted attractive apartments. But they also wanted the security of increasing levels of care when their circumstances changed. NovaCare, therefore, developed an innovative model allowing residents to remain in their apartments while accessing increasing levels of care.

But NovaCare did not merely have an idea.

It, therefore, built something. It developed the architectural implementation. It created apartment configurations. It developed detailed specifications. It is considered accessibility. It developed a care infrastructure. It created operational procedures. It prepared diagrams, presentations and written material. It developed distinctive branding. It refined the model over time. It implemented the model.

And, importantly, NovaCare followed good IP advice. It asked: “What intellectual property have we created?” Then: “What of that intellectual property can and should be protected?”

The company protected the available IP. That was not an optional legal indulgence. It was part of building the business. The company's intellectual property became one of the assets underpinning its competitive position. Then the market noticed.

The flattering moment that becomes frightening

At first, NovaCare's founders were delighted. Competitors were talking about the same general problem. The market was beginning to recognise the value of ageing in place.

Then one competitor appeared with a strikingly similar proposition. Let's call it Grandstone. Grandstone's residents could remain in their apartments as their care needs increased. Care was available on-site. The accommodation incorporated infrastructure capable of supporting higher levels of care. The marketing was remarkably familiar.

Then another competitor launched a similar offering. Then another. Then another. NovaCare's board became increasingly alarmed. “Didn't we protect this?” Yes. “So why are they doing it?” Because IP protection and infringement prevention are two different things.

That distinction deserves to be understood properly. Protection is not a force field. An IP right gives you a legal position. It does not control the behaviour of other human beings. A competitor can decide to comply. A competitor can decide to modify its conduct. A competitor can negotiate. A competitor can obtain a licence. A competitor can challenge the validity or scope of your rights. And, yes, a competitor can simply decide to take the risk. It might reason: “They probably won't sue.” “They can't afford to sue us.” “Even if they do, this will take years.” “By the time they win, we've already established ourselves in the market.”

This is not a theoretical problem. It is one of the central realities of IP enforcement. The existence of a right does not guarantee obedience.

But—and this is the critical point—the fact that somebody may ignore your right does not make the right worthless. Quite the opposite.

Without the right, you may have no meaningful ownership to enforce. Without ownership, there may be no exclusivity. Without exclusivity, there may be little leverage. Without leverage, your carefully developed innovation can become simply another idea that everybody is free to exploit. That is why protection comes first. First, understand exactly what you own. When NovaCare's lawyer investigates Grandstone, the first question is not: “How similar are they?”

It is: “What exactly does NovaCare own?” This is a deceptively important question.

An innovative business often talks about “its IP” as though IP were one thing.

It is not copyright, trade marks and distinctive branding, registered designs, where applicable patents, confidential information, Know-How, technical material, architectural drawings, specifications, manuals, diagrams, presentations, brand assets, contracts, licences and assignments

Some things may be legally protectable. Some may not. Some may be protected automatically. Some need registration. Some may be valuable precisely because they remain confidential. Some may be functional. Some may be dictated by regulation. Some may simply be ideas. The job is to map the territory.

You cannot necessarily own the idea, but you can own much of what makes the idea yours

NovaCare may have been the first business to develop the broad concept of allowing residents to age in place while receiving increasing care. That may be commercially significant.

But being first does not necessarily give NovaCare a monopoly over the abstract concept itself. Copyright, for example, generally protects original expression rather than an idea, system, business model or concept as such.

So NovaCare cannot simply announce: “We invented ageing in place. Nobody else may do it.” The same applies to features dictated by regulation, engineering, safety, accessibility, or practical necessity. This distinction is not a weakness in IP law. It is fundamental to how IP law works.

The law seeks to reward and protect innovation without giving one business a monopoly over everything that flows from a general idea. So NovaCare's lawyers make a distinction between the concept, the functional solution, the regulatory requirement, the particular original expression and implementation of the concept. That distinction may determine whether NovaCare has a case.

The difference between “similar” and “copied”

Grandstone may look remarkably similar to NovaCare. But similarity alone does not necessarily establish infringement. The investigation therefore becomes forensic. NovaCare's original material is placed beside Grandstone's later material. The lawyers examine:

Architecture — Are particular layouts, spatial relationships or design solutions reproduced?

Written material — Has particular wording or original written material been taken?

Diagrams — Are NovaCare's original diagrams reproduced?

Specifications — Are distinctive specifications or documentation substantially replicated?

Selection and arrangement — Has Grandstone reproduced an original selection or arrangement rather than merely adopting the same general concept?

Distinctive features — Are there similarities that are unnecessary to achieve the same functional outcome?

Functional features — Are the similarities simply inevitable consequences of regulation, engineering or ordinary practice?

That last distinction matters enormously. Two businesses can independently arrive at the same functional solution. That does not necessarily mean one copied the other. But if an unusual, distinctive and unnecessary feature appearing in NovaCare's earlier material subsequently appears in Grandstone's material, the question becomes considerably more interesting.

The legal question changes from: “They are doing something similar.” to: “Have they reproduced a substantial part of something that NovaCare actually owns?”

Then, investigate the invisible part of the story: access

Suppose Grandstone's plans contain something remarkably similar.

The next question is: “How did Grandstone get there?” NovaCare, therefore, investigates chronology. When did NovaCare create its material? When did it implement the innovation? When did it first publicly promote it? When did Grandstone begin developing its project?         When were Grandstone's architects appointed? When were its plans prepared? Who were its consultants? Had anyone at Grandstone previously worked with NovaCare? Had anyone visited NovaCare? Had they attended an industry presentation? Had NovaCare's brochures or presentations circulated within the industry? Had there been meetings, emails or discussions? Was there another plausible route of access?

The point is not to assume copying merely because two businesses look similar. The point is to identify evidence capable of supporting—or weakening—the inference of copying. That distinction is essential.

Your evidence file may be almost as important as your registration

NovaCare now appreciates another important principle. An IP strategy is not simply a collection of certificates. It is also an evidence system. NovaCare builds a historical record showing:

·        what was created;

·        who created it;

·        when it was created;

·        who owned it;

·        when it was implemented;

·        how it evolved;

·        when it was published;

·        who received it;

·        who had access to it;

·        and what the business was actually doing at each stage.

This can become extremely valuable. Imagine the difference between saying: “We invented this before them,” and saying: “Here is the original document. Here is its creation date. Here is the author. Here is our ownership record. Here is the presentation we gave in 2018. Here is the material that was circulated. Here is the evidence that your consultant attended the presentation. Here is the latter material in which the distinctive elements appear.”

The second position is vastly more useful. Evidence turns assertion into leverage.

NovaCare discovers the ownership trap

There is another question that must be answered before NovaCare becomes too excited.

Who owns the architectural drawings? NovaCare paid the architect. But the drawings contain the architect's copyright notice. “But we paid for them!”. That is not necessarily the end of the legal analysis.

NovaCare must examine its contracts and ask: Was copyright assigned? Was a licence granted? What kind of licence? Is it exclusive? What rights does NovaCare actually have? Who can enforce? Does the architect need to be involved? and ask

This is a lesson every innovative business should learn early: Having paid for something does not necessarily answer the question of who owns the intellectual property in it. Ownership needs to be established deliberately. This is not administrative housekeeping.

It is enforcement infrastructure.

Now we reach the real dilemma

NovaCare now knows considerably more. It has protected its IP. It understands what it owns. It has strengthened its evidence. It has identified potentially significant copying. But it has twenty competitors. It cannot sue twenty competitors. So what should it do? This is where many businesses make their biggest strategic mistake. They assume the only choices are:

Option A: Sue everyone. This is impossible and commercially irresponsible.

Option B: Do nothing. It is equally unattractive.

But there is a third option. Actually, there are several. And together they form a much more sophisticated strategy.

Option C: PROTECT. MONITOR. TRIAGE. LEVERAGE. ENFORCE. MONETISE.

1. PROTECT — before you need protection

This part is non-negotiable. If an asset can legitimately and commercially be protected, protect it. Identify the IP. Register what should be registered. Document what should be documented. Protect confidential information. Control access. Use appropriate contractual arrangements. Obtain assignments where required. Put licences in place where appropriate.

Protect the brand. Consider design protection. Preserve evidence. Do not wait until a competitor appears.

By then, some opportunities may have disappeared. The reason you protect IP is not that you know you will sue somebody next year. You protect it because ownership and exclusivity are foundational components of the business.

2. MONITOR — because you cannot enforce what you do not see

Once protected, watch the market. Monitor competitors. Monitor new products. Monitor websites. Monitor advertising. Monitor industry publications. Monitor new developments. Monitor branding. Monitor presentations. Monitor public documents.

And when something suspicious appears: preserve it. Take dated copies. Keep the brochure. Save the website. Record the advertisement. Obtain plans where legitimately available. Document what you saw and when you saw it. Why? Because evidence disappears. Websites change. Marketing campaigns end. People leave organisations. Documents are replaced. Memories deteriorate.

A competitor's new website today may be very useful evidence. Three years later, it may have vanished. Monitoring is therefore not about being paranoid. It is about maintaining the ability to make an informed decision.

3. TRIAGE — not every competitor deserves the same response

This is where the strategy becomes scalable. Imagine NovaCare has twenty competitors. They are not all the same.

Competitor A

Uses the same broad concept. No evidence of access. No obvious copying of protected expression. Monitor.

Competitor B

Uses some unusually similar features. There are questions about access. Evidence is incomplete. Investigate.

Competitor C

Appears to have used confidential NovaCare material. Immediate legal assessment.

Competitor D

Has adopted confusingly similar branding. Trade mark and branding assessment.

Competitor E

Appears to have reproduced distinctive NovaCare material, has strong evidence of access and represents a significant commercial threat. Potential enforcement target.

This is portfolio management.

You do not spend the same amount of money on every problem.

You allocate resources based on legal strength, evidence, commercial impact, strategic importance, deterrence value, and cost.

4. LEVERAGE — Use the rights before you use the courtroom

You do not need to litigate to enforce your commercial position.

There is a large territory between “we noticed something” and “we commenced litigation”.

Instead focus on evidence preservation, regular and ongoing investigation, make discussions confidential by having a Non-Disclosure-Agreement (NDA) signed.

Request clarification; use formal correspondence, negotiations, undertakings, commercial settlements, and changes to branding or materials; and engage in licensing discussions to leverage the business.

The objective is to make the competitor understand that the issue is real. There is a profound difference between “You stole our idea” and “These are the specific rights we own. This is the material in which those rights arise. This is the material we believe has been reproduced. This is evidence of our ownership and chronology. These are the commercial options available to resolve the matter.” The second conversation creates leverage.

Rights create credibility. Evidence creates pressure. Credibility and pressure create negotiating power.

5. ENFORCE SELECTIVELY — because selective does not mean weak

Now imagine NovaCare identifies one competitor where everything lines up. The rights are strong. The ownership is clear. The evidence is good. Access can potentially be established. The infringement is commercially significant. The competitor is important. A successful outcome could have a deterrent effect beyond that individual competitor.

That may be the case to pursue. Not because NovaCare has promised to sue everyone.

Because this particular case earns the right to consume resources. Litigation should be treated as an investment decision, not an emotional reaction.

Ask:

·        How strong is the right?

·        How strong is the evidence?

·        What exactly has been copied?

·        What remedy is realistically available?

·        What is the commercial damage?

·        What will enforcement cost?

·        What is the likelihood of an early settlement?

·        What is the deterrent effect?

·        Does winning this case change the behaviour of other competitors?

·        What is the cost of doing nothing?

The economics change when you stop trying to sue everyone

Suppose NovaCare believes that fully contested litigation could cost hundreds of thousands of dollars. That sounds frightening. And it should. Litigation is expensive. But the conclusion should not be: “Therefore, IP protection is useless.” The correct conclusion is: “Therefore, we need to be exceptionally disciplined about when we litigate.”

That is precisely why the first investment should often be a forensic investigation. Before spending $300,000, determine whether there is a sufficiently strong evidentiary pathway to justify spending $300,000. Spend money first to answer: “Do we have a case worth investing in?”, not: “Let's spend money and find out.” That is commercially intelligent legal work.

6. Make one enforcement action count for more than one competitor

Competitors watch each other. Suppose NovaCare pursues one strong case. The case demonstrates that NovaCare has identifiable rights, understands those rights, has evidence, and monitors the market. It also says: NovaCare is prepared to act and will not simply tolerate appropriation of its protected assets.

Other competitors notice. NovaCare has not sued twenty businesses. It may not need to. The market has learned something. This is deterrence. The objective is not “NovaCare will sue everyone.” The objective is: “NovaCare will not necessarily sue everyone—but if you cross the line, NovaCare has the ability and willingness to act where it matters.” That can be enough to alter behaviour. One carefully selected enforcement action can therefore have a market-wide effect.

7. And then comes the unexpected opportunity: licensing.

Now, suppose another competitor says, “We want to continue using the model. We don't want a dispute. Can we reach an arrangement?” This is the moment when an IP dispute can become a commercial opportunity. Instead of: “Stop using it.”

The conversation can sometimes become: “Let's discuss a licence.” That could potentially involve, depending on the rights and circumstances involving particular protected material, Know-How, designs, branding, systems, territories, and fields of use, quality standards, reporting, royalties, restrictions on further use, and other commercial terms.

Not every competitor should be licensed. Sometimes licensing would weaken the competitive position. Sometimes the rights are insufficient. Sometimes the conduct is too damaging. Sometimes litigation is the better option.

But licensing should be on the strategic menu. Because there is something very interesting about a competitor copying your innovation: they may have just demonstrated that your innovation has commercial value. Why automatically destroy that value? Where appropriate, monetise it.

The copier can become the customer

This is perhaps the most counterintuitive idea in the entire strategy. Imagine NovaCare spends $250,000 fighting a competitor. Or imagine NovaCare spends a fraction of that amount negotiating a commercial arrangement that turns the competitor into a paying licensee.

The second outcome may be vastly better. Again, it is not always possible. But the strategic possibility changes the mindset.

The competitor is no longer merely the enemy. It may be the market validating your innovation. And potentially: a new source of revenue. That is what it means to treat IP as a commercial asset rather than merely a legal weapon.

But what if they simply take their chances?

This is the hardest case. Suppose the competitor's lawyer has reviewed everything. The competitor knows there is a risk. And the board says: “Sue us! We wanna see you try!”

What now? The answer is not to pretend that IP rights automatically solve the problem.

It doesn't. The competitor has made a commercial calculation. You must make one too.

And that calculation should be based upon: if the case is weak, perhaps you do nothing. If the case is strong but the competitor is irrelevant, perhaps you monitor. If the case is strong and strategically important, perhaps you should act. If the case is strong and the competitor wants continued access, perhaps you can license.

The key is that the competitor gets to choose whether to take its chances—but you get to choose how you respond.

This is why “IP is useless because we cannot enforce it against everyone” is logically wrong

Consider the argument: We cannot sue everyone. True. Therefore, our IP has no value. That does not follow.

The argument assumes that the only value of IP is the ability to obtain a court judgment against every infringer. But IP can create value long before a court is involved. It establishes ownership. It can create exclusivity. It can support negotiations. It can deter competitors. It can support licensing. It can strengthen a brand. It can increase the value of the business. It can help attract investment. It can support partnerships. And, when necessary, it can provide the legal foundation for enforcement. The right does not become worthless simply because you use it selectively.

Quite the opposite. Selective use may be precisely what makes the strategy economically rational.

Think of IP as infrastructure, not insurance

This is perhaps the best way to think about the issue. IP is not an insurance policy where you pay a premium and expect the insurer to make the problem disappear. Nor is it a giant legal fence that physically prevents competitors from crossing it. It is business infrastructure.

The registration is one component. Ownership is another. Contracts are another. Confidentiality is another. Know-how is another. Branding is another. Evidence is another. Monitoring is another. Enforcement is another. Licensing is another. Continuing innovation is another. Together, they create something much more valuable than a certificate.

They create a defensible commercial position.

The IP perimeter

NovaCare, therefore, begins to think of its protection as an IP perimeter.

Inside the perimeter are the things that make its implementation distinctive, namely:

·        the original documentation.

·        the brand.

·        the designs.

·        the proprietary systems.

·        the know-how.

·        the confidential information.

·        the contractual rights.

·        the protected works.

·        the evidence.

·        the continuing developments.

Outside the perimeter are things competitors may legitimately do independently, which are:

·        general concepts.

·        public information.

·        functional requirements.

·        regulatory requirements.

·        ideas that cannot legitimately be monopolised.

This is important because a good IP strategy does not try to claim everything.

It identifies where the legal and commercial boundary actually lies. Then it makes that boundary as strong as possible.

The moving perimeter

And NovaCare does one more thing. It keeps innovating. While competitors copy version one, NovaCare develops version two.

While they imitate the original implementation, NovaCare improves the customer experience.

It develops new systems. New designs. New processes. New technology. New branding. New Know-How.

And then it protects those developments too. This creates a moving perimeter. Competitors can copy yesterday. But NovaCare is already building tomorrow. This may ultimately be the strongest defence of all.

What innovative businesses should actually do?

So, if you are running an innovative business, what should you do? Not theoretically. Practically.

BEFORE anyone copies you

1. Conduct an IP audit. Identify every potentially protectable asset. Do not stop at patents and trade marks.

2. Classify the assets. Separate patents, designs, trade marks, copyright, confidential information, know-how, contractual rights and other relevant assets.

3. Protect the important assets. Register where appropriate and properly preserve unregistered rights.

4. Establish ownership. Check employees, contractors, consultants, architects, designers, agencies and suppliers. Do not assume that paying someone means you own their IP.

5. Fix the contracts. Use appropriate IP assignment, licensing, confidentiality and permitted-use provisions.

6. Build the evidence file. Create a dated record of development, authorship, ownership, implementation, publication and disclosure.

7. Build the brand. Make the market understand who created the innovation.

AFTER competitors appear

8.    Monitor. Watch the market continuously.

9.    Preserve. Capture potentially relevant evidence while it exists.

10.  Investigate. Do not accuse merely because something looks similar.

11.  Separate the concept from the protected expression. Ask exactly what has been copied.

12. Investigate access and chronology. How could the competitor have obtained or encountered your material?

13. Confirm ownership. Make sure the right you intend to rely upon actually belongs to you.

14. Triage. Rank competitors according to legal strength, evidence, commercial impact and strategic importance.

15. Choose the response. Monitor, investigate, negotiate, seek undertakings, license, enforce, or do nothing.

16. Select enforcement targets carefully. Choose the cases where enforcement can produce the greatest legal and commercial return.

17. Make enforcement count. Where appropriate, choose cases capable of creating broader

    deterrence.

18. Consider licensing. Where appropriate, turn the market's appetite for your innovation into revenue.

19. Keep innovating. Keep moving the perimeter.

Protection is inevitable. Enforcement is strategic.

This is ultimately the distinction that every innovative business should understand.

PROTECTION IS A MUST.

If you have valuable IP that can legitimately be protected, failing to protect it can be commercially reckless. You cannot expect to build a valuable innovation and simply leave the underlying rights undefined. You need ownership. You need protection. You need evidence. You need control. You need a defensible position. But protection is not a guarantee of compliance. Competitors remain free to make their own decisions.

Some will comply.

Some will negotiate.

Some will test the boundaries.

Some will infringe deliberately.

Some will simply take their chances.

That is why enforcement must be strategic. You do not need to sue everyone. You need to know who matters, what they have done, what rights you have, what you can prove, what it will cost, what you can gain, and what message the outcome will send to the market. And sometimes the best result is not a judgment. It is a licence.

The ultimate IP strategy

NovaCare's board eventually stops asking: “Why are people copying us if we protected our IP?” It asks a much better question: “How do we use the IP we have protected to maximise the value of our innovation?”

That question produces a completely different strategy. Protect broadly. Establish ownership. Build evidence. Monitor continuously. Distinguish ideas from protectable expression. Investigate before accusing. Triage competitors. Create credible leverage. Enforce selectively.

Use one strong enforcement action where it can create wider deterrence.

Negotiate where negotiation is better. License where licensing makes commercial sense. And keep innovating!

The objective is not to create an impossible promise that nobody will ever copy you. The objective is to make sure that when they do, you are not powerless. You know what belongs to you. You can prove it. You understand the boundaries. You can decide what matters. You can decide whom to pursue. You can decide whom to negotiate with. You can decide whom to license. And you can decide when litigation is worth the investment. That is what properly protected IP gives you. Not a guarantee that competitors will behave.

Something more practical: choice. And choice is leverage.

The final paradox

There is, finally, a beautiful paradox in successful innovation.

If nobody ever copies your innovation, perhaps the market has not yet recognised its value. When everybody starts copying it, you may have discovered something commercially important. The mistake is to conclude: “Everyone is copying us, therefore our IP protection was pointless.” The better response is: “Everyone wants what we created. We protected it. Now let's use that protection intelligently.”. Your competitors may choose to take their chances. You cannot control that.

But you can control whether you have built a position in which those chances are: legally risky, commercially unattractive, negotiable, licensable, or, where justified, worth litigating.

That is the answer to the dilemma. Not: protect or enforce. Not: sue everyone or surrender. And certainly not: don't protect because litigation is expensive.

The answer is: PROTECT. MONITOR. EVIDENCE. TRIAGE. LEVERAGE. LICENSE. ENFORCE SELECTIVELY. KEEP INNOVATING!

Because IP protection is the foundation of the business. Enforcement is the strategy for what happens when someone tests that foundation. And the smartest IP strategy is the one that gives the innovator enough strength, evidence and commercial leverage that it does not have to fight every battle to win the war.